A Pharmacokinetic and Phase II Study of Pertuzumab in Combination With Trastuzumab And Eribulin (Halaven) in Patients With Advanced HER2-Positive Breast Cancer
Not Applicable
- Conditions
- Advanced or recurrent human growth factor receptor 2 (HER2) -positive breast cancer patients
- Registration Number
- JPRN-UMIN000012375
- Lead Sponsor
- The Cancer Institute Hospital of JFCR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 53
Inclusion Criteria
Not provided
Exclusion Criteria
(1) Physician judged improper to entry this trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective Response Rate
- Secondary Outcome Measures
Name Time Method